GlassScriptPhysician profile
Mimi A Kingery
NPI 1790065035
$8,605.17
in general payments reported to CMS, 2019-2025
35 companies · $2,123 in 2025
The $2,123 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,271 · 2022: $1,530 · 2023: $1,835 · 2024: $1,846 · 2025: $2,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,753 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,753.47 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,849.41 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $952.15 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $717.40 | 2021-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $435.47 | 2021-2024 | |
| Madrigal Pharmaceuticals | $390.37 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.14 | 2021-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $310.52 | 2021-2024 | |
| Pfizer INC. | $291.27 | 2021-2025 | |
| Celgene Corporation | $234.84 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $203.08 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $200.82 | 2021-2025 | Ocaliva |
| Si-Bone, INC. | $152.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $132.72 | 2023 | Zeposia |
| Evoke Pharma, INC. | $125.94 | 2022-2025 | Gimoti |
| Lilly USA, LLC | $123.83 | 2024-2025 | Omvoh |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $121.76 | 2021-2023 | |
| Shockwave Medical, INC | $101.20 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $97.30 | 2023-2025 | Evenity, Avsola |
| Phathom Pharmaceuticals, INC. | $96.17 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $79.81 | 2023-2024 | Dupixent |
| Fresenius Kabi USA, LLC | $79.64 | 2023-2024 | Idacio |
| Medtronic, INC. | $77.08 | 2024 | Interstim |
| Ardelyx, INC. | $69.40 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $63.25 | 2023 | Supera |
| Redhill Biopharma INC. | $51.47 | 2021-2022 | |
| Genzyme Corporation | $51.28 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $48.94 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $47.60 | 2021 | |
| Mallinckrodt Hospital Products INC. | $41.70 | 2022 | |
| Ferring Pharmaceuticals INC. | $32.17 | 2024-2025 | Rebyota |
| Organon LLC | $20.76 | 2023 | Hadlima |
| Braintree Laboratories, INC. | $17.60 | 2023 | Suflave |
| Alcresta Therapeutics, INC. | $16.12 | 2024 | Relizorb |
| Exact Sciences Corporation | $14.72 | 2023 | Cologuard Collection Kit |
| Pharmacosmos Therapeutics INC. | $14.57 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Kingery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.